APOE4: the Beat the Odds study
APOE4 can raise the odds of late-onset Alzheimer's disease. Phoenix studies the interventions and everyday choices behind carriers who are doing better over time.
The Beat the Odds Study asks one question: what changed after APOE4 carriers changed their medications, supplements, sleep and daily habits? Here is what moved, who it moved for, and what else was going on at the time.
How to read this
Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.
Read the full methods and limitsRelease 001 is out
Phoenix has published the final 43-page report, built from the latest reviewed result set.
The new report shows each focal intervention, the member's full recorded stack, why Phoenix selected that intervention, the measured result, and the limits of the attribution.
Get the Beat the Odds Study
Enter your email and APOE status to get the 43-page report.
What the current evidence supports
No supplement has shown community-level efficacy yet.
Several individual results are promising, but comparable protocols need to repeat across more members before Phoenix calls them a community-level effect.
A result is left out when assays cannot be compared, timing does not fit, the change is within expected variation, or the proposed intervention has no plausible mechanism for the outcome.
Studies with our partners
Phoenix runs its own member studies with the devices and tests it recommends, and every result is published in full on its own page.
Be part of the research. Find what works for you.
Start with Phoenix's seven-minute assessment to join. Members can connect a baseline, a change, adherence, follow-up, and the result. Each result can help Phoenix AI improve what it suggests testing next, for you and for carriers with a similar profile. Together, we are building Phoenix's goal: the largest ongoing member-led longitudinal study of how APOE4 carriers beat the odds.